|Institutional Source||Beutler Lab|
|Gene Name||polo like kinase 1|
|Essential gene?||Essential (E-score: 1.000)|
|Stock #||R4887 (G1)|
|Chromosomal Location||122159439-122169873 bp(+) (GRCm38)|
|Type of Mutation||missense|
|DNA Base Change (assembly)||T to C at 122168605 bp (GRCm38)|
|Amino Acid Change||Valine to Alanine at position 411 (V411A)|
|Ref Sequence||ENSEMBL: ENSMUSP00000033154 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000033153] [ENSMUST00000033154] [ENSMUST00000206198] [ENSMUST00000206470]|
AA Change: V411A
PolyPhen 2 Score 0.997 (Sensitivity: 0.41; Specificity: 0.98)
AA Change: V411A
|Coding Region Coverage||
FUNCTION: The Ser/Thr protein kinase encoded by this gene belongs to the CDC5/Polo subfamily. It is highly expressed during mitosis and may play a role in DNA replication during S phase. This gene is expressed in all embryonic tissues, but restricted to thymus and ovaries in adult tissues. Homozygous knockout mice were embryonic lethal, suggesting that this gene is important for early embryonic development. This gene is thought to be a potential oncogene because it is overexpressed in a variety of tumors and tumor cell lines. Depletion of this protein in cancer cells has been shown to inhibit cell proliferation and suppress oncogenic transformation; hence, it is a target for cancer therapy. [provided by RefSeq, Sep 2015]
PHENOTYPE: Mice homozygous for a null mutation display lethality before implantation, embryonic growth arrest, and impaired mitosis. Mice heterozygous for a null mutation display increased tumor incidence and increased incidence of aneuploidy. [provided by MGI curators]
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in Plk1||
(F):5'- TAGAGTACAGGGGCTCACTC -3'
(R):5'- AGGCCTTGGAAGAACTCAGTAG -3'
(F):5'- CTCACTCGTGATGAAGTGGGC -3'
(R):5'- GAACTCAGTAGTACAATGCTTGCC -3'